Search
D-glyceraldehyde 3-phosphate
go.drugbank.com/drugs/DB02263ExperimentalAn aldotriose which is an important intermediate in glycolysis and in tryptophan biosynthesis.
rhMBL
go.drugbank.com/drugs/DB05237InvestigationalrhMBL is a protein therapeutic being developed by Enzon for the prevention and treatment of severe infections in individuals with low levels of Mannose-Binding Lectin (MBL).
Linaprazan glurate
go.drugbank.com/drugs/DB21534InvestigationalLinaprazan glurate is under investigation in clinical trial NCT07037875 (A Study Comparing the Effect and Safety of Linaprazan Glurate to Lansoprazole in Participants With Erosive Esophagitis (EE) Due … The usage of the INN stem '-prazan' in the name indicates that Linaprazan glurate is a proton pump inhibitor, not dependent on acid activation.
OBE101
go.drugbank.com/drugs/DB05080ExperimentalIt is a new formulation that is based on the vertigo medication, Betahistine. … Obecure is repurposing betahistine, which is an H1 receptor agonist and partial H3 receptor antagonist for the treatment of obese individuals and for other weight management indications.
Butaperazine
go.drugbank.com/drugs/DB13213ApprovedButaperazine was approved in 1967 [L5143], and possibly discontinued in the 1980s [T397].
Dansylamide
go.drugbank.com/drugs/DB02866ExperimentalCategories: Compounds used in a research, industrial, or household settingBorage oil
go.drugbank.com/drugs/DB11238ApprovedBorage oil may be found in foods or in skin care products. … Borage oil is used as an herbal treatment of skin disorders including eczema, seborrheic dermatitis, and neurodermatitis as well as other inflammatory, cardiovascular and endocrine disorders, although
MDX-1303
go.drugbank.com/drugs/DB05945InvestigationalMDX-1303 is a fully human antibody against the inhalation anthrax, the most lethal form of illness in humans caused by the Bacillus anthracis bacterium, and targets a protein component of these lethal
4'-Methylene-5,8,10-trideazaaminopterin
go.drugbank.com/drugs/DB05616InvestigationalCH-1504 is a an antirheumatic agent that has been shown in vitro to be a nonpolyglutamylatable and nonhydroxylatable antifolate that is more efficiently taken up into cells by the reduced folate carrier
CNS-5161
go.drugbank.com/drugs/DB05824ExperimentalCNS 5161 is a blocker of the NMDA ion channel and has completed Phase IIa proof of concept clinical trials as a novel compound for the treatment of neuropathic pain.